Skip to content
In-vivo Drug Evaluation
In-vivo Drug Evaluation


In-vivo Drug Evaluation

NHRF/ICB will provide access to infrastructures and expertise on established models relevant for preclinical evaluation of drugs/therapeutics on cancer, using xeno-transplants (including Patient Derived Xenografts-PDX) and ex-vivo organoid/spheroid cultures (including Patient Derived Spheroids-PDS). Evaluation of the predictive capacity of PDS and PDX to the therapeutic response of the original tumor will be performed. Further, development of novel rational combinatorial therapeutic protocols of anti-cancer drugs at the preclinical stage for each individual tumor will be performed. This is expected to provide oncologists with additional evidence for the preclinical individual tumor vulnerability, which may be later be translated to efficient therapies.


Partner Institute

Vassilis Zoumpourlis

Vassilis Zoumpourlis

Institute of Chemical Biology
National Hellenic Research Foundation (NHRF)
48 Vassileos Constantinou Avenue
11635 Athens, Greece
Tel:  +30 210 7273730;
Fax: +30 210 7246677